Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
JERUSALEM, October 20/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.(OTCBB: ORMP.OB; http://www.oramed.com), a developer of oral drug delivery systems, announced today that its poster entitled "A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model," has been accepted for presentation at the Diabetes Technology Society's Ninth Annual Meeting in San Francisco, California between November 5-7, 2009.
"The selection of Oramed as one of the companies to present at the
Diabetes Technology Conference is a wonderful opportunity for us to
demonstrate our technology to the world's leading diabetes scientists," said
Nadav Kidron, Oramed CEO.
Oramed's abstract will be presented on Thursday November 5, 2009, at 5:30
PM. The poster will be available for viewing throughout the conference.
For more information about the Diabetes Technology Society's Ninth Annual
Meeting, please visit http://www.diabetestechnology.org/
For more information about Oramed Pharmaceuticals, please visit
http://www.oramed.com
